|
Sep 7
|
UPDATE 2-Alnylam's gene-silencing drug cuts blood pressure in mid-stage trial
|
|
Sep 7
|
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
|
|
Sep 6
|
CRISPR Therapeutics AG (CRSP) Down 5.3% Since Last Earnings Report: Can It Rebound?
|
|
Sep 6
|
First Set of Recommendations Advocating for the Holistic Care of People Living with hATTR Amyloidosis Developed by International Panel of Patient Advocates and Healthcare Professionals
|
|
Jul 24
|
Alnylam, Roche team up in $3B+ deal over hypertension drug
|
|
Jul 24
|
Alnylam (ALNY) to Co-Develop Hypertension Drug With Roche
|
|
Jul 24
|
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
|
|
Jul 21
|
Why Shares of BridgeBio Pharma Skyrocketed This Week
|
|
Jul 20
|
Will Alnylam Pharmaceuticals (ALNY) Report Negative Q2 Earnings? What You Should Know
|
|
Jul 20
|
Here's Why You Should Add Alnylam (ALNY) Stock to Your Portfolio
|
|
Jul 20
|
Alnylam to Webcast Conference Call Discussing Second Quarter 2023 Financial Results
|
|
Jul 19
|
Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine
|
|
Jul 17
|
Why Alnylam Pharmaceuticals Topped the Market Today
|
|
Jul 17
|
BridgeBio Launches 76% And Pulls Its Rival Higher On Bullish Heart Drug News
|
|
Jul 17
|
Alnylam (ALNY) Posts Upbeat Data From Alzheimer's Disease Study
|
|
Jul 17
|
BridgeBio unveils positive results from rare heart disease drug trial, shares jump
|
|
Jul 17
|
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
|
|
May 22
|
Alnylam (ALNY) Reports Positive Results From APOLLO-B Study
|
|
May 20
|
Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
|